{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:10:23Z","timestamp":1744294223438},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1038\/nrclinonc.2009.15","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T02:35:01Z","timestamp":1238466901000},"page":"237-240","source":"Crossref","is-referenced-by-count":8,"title":["Restoration of chemosensitivity by bortezomib: implications for refractory myeloma"],"prefix":"10.1038","volume":"6","author":[{"given":"Chor Sang","family":"Chim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Yan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony W.","family":"Shek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnrclinonc200915_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2141.2004.04834.x","volume":"124","author":"R Soutar","year":"2004","unstructured":"Soutar, R.  et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br. J. Haematol. 124, 717\u2013726 (2004).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc200915_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1600-0609.2005.00531.x","volume":"75","author":"E Terpos","year":"2005","unstructured":"Terpos, E.  et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur. J. Haematol. 75, 376\u2013383 (2005).","journal-title":"Eur. J. Haematol."},{"key":"BFnrclinonc200915_CR3","first-page":"609","volume":"87","author":"A Alegre","year":"2002","unstructured":"Alegre, A.  et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 87, 609\u2013614 (2002).","journal-title":"Haematologica"},{"key":"BFnrclinonc200915_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","volume":"34","author":"R Zeiser","year":"2004","unstructured":"Zeiser, R.  et al. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 34, 1057\u20131065 (2004).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrclinonc200915_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1600-0609.2004.00331.x","volume":"73","author":"G Damaj","year":"2004","unstructured":"Damaj, G.  et al. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur. J. Haematol. 73, 402\u2013406 (2004).","journal-title":"Eur. J. Haematol."},{"key":"BFnrclinonc200915_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrc746","volume":"2","author":"WM Kuehl","year":"2002","unstructured":"Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175\u2013187 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc200915_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima, T.  et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7, 585\u2013598 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc200915_CR8","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860\u20131873 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc200915_CR9","doi-asserted-by":"crossref","unstructured":"[No authors listed.] Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J. Clin. Oncol. 16, 3832\u20133842 (1998).","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"BFnrclinonc200915_CR10","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson, P. G.  et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609\u20132617 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc200915_CR11","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson, P. G.  et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487\u20132498 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc200915_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","volume":"129","author":"HE Oakervee","year":"2005","unstructured":"Oakervee, H. E.  et al. PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 129, 755\u2013762 (2005).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc200915_CR13","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2003-06-2151","volume":"103","author":"AC Bharti","year":"2004","unstructured":"Bharti, A. C.  et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103, 3175\u20133184 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc200915_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades, N.  et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377\u20132380 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc200915_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000226019","volume":"42","author":"DC Case Jr","year":"1985","unstructured":"Case, D. C. Jr.  et al. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol). Oncology 42, 137\u2013140 (1985).","journal-title":"Oncology"},{"key":"BFnrclinonc200915_CR16","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","volume":"108","author":"MV Mateos","year":"2006","unstructured":"Mateos, M. V.  et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study. Blood 108, 2165\u20132172 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc200915_CR17","first-page":"76","volume":"110","author":"JF San Miguel","year":"2007","unstructured":"San Miguel, J. F.  et al. MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisolone (VMP) with melphalan-prednisolone (MP) in newly diagnosed multiple myeloma [abstract 76]. Blood (ASH annual meeting abstract) 110, 76 (2007).","journal-title":"Blood (ASH annual meeting abstract)"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.15","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:02:30Z","timestamp":1684468950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["BFnrclinonc200915"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.15","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}